Author

Debora C. Manning

Institution: Veristat, LLC (United States)

Observed institution: Veristat, LLC (United States)

ORCID: 0009-0005-3248-8092

Observed ORCID: 0009-0005-3248-8092

OpenAlex ID: A5062605254

Cell-Based Ciliary Neurotrophic Factor Therapy for Macular Telangiectasia Type 2

2025 · Emily Y. Chew, Mark Gillies, et al. · NEJM Evidence · 41

Safety, tolerability, and pharmacokinetics of a single orally inhaled dose of PUR3100 , a dry powder formulation of dihydroergotamine versus intravenous dihydroergotamine: A Phase 1 randomized, double‐blind study in healthy adults

2024 · Susan Bodie, Aidan K. Curran, et al. · Headache The Journal of Head and Face Pain · 2

Pooled Analyses of Anatomic and Visual Function Data of Revakinagene Taroretcel-lwey in Participants with Macular Telangiectasia Type 2

2026 · Roger A. Goldberg, Debora C. Manning, et al. · Ophthalmology Retina

Works count: 3

Citation count: 43

H-index: 2

I10-index: 1